The global peptide therapeutics market was valued at $164 billion in 2026 and is projected to reach $295 billion by 2033. That’s a near-doubling in under a decade. And yet, the science, the marketing, the dosing protocols, and the content ecosystem are overwhelmingly built for one body: a man’s.
This isn’t opinion. It’s data.
An analysis of 1,433 trials with over 300,000 participants found that only 41.2% of participants were female. In industry-sponsored trials, women were just 39.2% of enrollees. In Phase I trials — where drug safety and dosing are first established — women represent as few as 22-29% of participants. And 80% of preclinical studies assessing drug safety and efficacy were conducted solely in male mice.
The consequence: women experience 1.5 to 1.7 times greater risk of adverse drug reactions than men. Between 1997 and 2000, 70% of drugs withdrawn from the U.S. market presented greater health risks for women. The drugs were tested on men. They failed in women. And the women paid the price.
If clinical trials broadly underrepresent women, the peptide space is an extreme case. Most popular peptides — BPC-157, TB-500, CJC-1295/Ipamorelin, MOTS-C — have virtually zero human clinical trial data in women specifically. Dosing protocols circulating online are derived from male bodybuilding communities. Peptide vendor marketing features shirtless men. And the content ecosystem — the blogs, YouTube channels, Reddit threads, and podcasts that shape how people learn about peptides — is almost entirely male-coded.
The disconnect is total. Women search symptom-first (“why am I so tired”). The peptide internet speaks peptide-first (“best GH secretagogue stack”). Women want to know if it’s safe during perimenopause. The peptide internet assumes you’re a 35-year-old male athlete.
A 2025 report analyzing 159 women’s health nonprofits, content creators, and startups found widespread content suppression across major platforms: 84% had content removed from Meta, 64% from Amazon, and 66% from Google — even when content contained only anatomical language or clinical facts. Meanwhile, content for male-focused products like erectile dysfunction medication proliferates freely on the same platforms.
Women’s peptide education isn’t just underserved. It’s actively suppressed by the platforms that control how information reaches people.
The gender gap isn’t just a representation problem. It’s a safety problem. Women metabolize drugs differently. Estrogen modulates growth hormone secretion. Progesterone affects IGF-1 sensitivity. Body composition differs (higher body fat percentage, different volume of distribution). Hormonal cycles create variable pharmacokinetics that don’t exist in male subjects.
When a peptide’s safety and dosing are established in men and then applied to women without adjustment, you get unpredictable results: inadequate dosing (peptide doesn’t work as expected), excessive dosing (higher side effect rates), or completely missed interactions with female-specific hormonal systems.
This site exists because no one else built it. Zero dedicated, independent, editorially-driven peptide education resources for women existed before FemPeptides. Every competitor site — PeptideDeck, SeekPeptides, PeptidesInsider, AllAboutPeptides — writes for the male biohacker by default. The few articles about “peptides for women” are afterthoughts: single pages on otherwise male-coded sites.
FemPeptides is the first independent peptide education resource built for women from the ground up. Symptom-first language. Sex-specific dosing considerations. Research cited with honest evidence-level assessment. No fake personas, no shirtless stock photos, no bro-science.
The $164 billion peptide industry forgot about half the population. We didn’t.
Historical FDA policy banned women of childbearing potential from Phase I trials from 1977-1993. Even after the ban was lifted, the legacy persisted: pharmaceutical companies cite pregnancy risks, hormonal complexity, and liability concerns to justify excluding women. The peptide space is even more skewed because most peptides haven't gone through formal clinical trials at all — the available data comes primarily from male-dominated bodybuilding and biohacking communities.
Yes. Women experience 1.5-1.7x more adverse drug reactions than men across pharmaceuticals generally. When safety and dosing data is established primarily in male subjects, women face unpredictable responses. This applies to peptides as well: dosing protocols circulating online are based on male physiology and may be inappropriate for women, especially during hormonal transitions like perimenopause.
FemPeptides is the first independent, dedicated peptide education resource built for women. Competitor sites like SeekPeptides and PeptideDeck have single articles about 'best peptides for women' but are otherwise male-coded in language, imagery, use cases, and dosing guidance. Clinic sites like Meto.co and Superpower.com have strong women's content but are selling services, not providing independent education.
Advocate for sex-specific research by supporting organizations pushing for gender parity in clinical trials. Choose providers who understand female physiology and adjust protocols accordingly. Don't accept male-derived dosing protocols without discussion. Report your experiences — anecdotal data from women using peptides contributes to the knowledge base while formal trials catch up.